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Background: Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor with poor clinical
outcome. Identification and development of new markers could be beneficial for the diagnosis and prognosis of
GBM patients. Deregulation of microRNAs (miRNAs or miRs) is involved in GBM. Therefore, we attempted to identify
and develop specific miRNAs as prognostic and predictive markers for GBM patient survival.
Methods: Expression profiles of miRNAs and genes and the corresponding clinical information of 480 GBM samples
from The Cancer Genome Atlas (TCGA) dataset were downloaded and interested miRNAs were identified.
Patients’ overall survival (OS) and progression-free survival (PFS) associated with interested miRNAs and
miRNA-interactions were performed by Kaplan-Meier survival analysis. The impacts of miRNA expressions and
miRNA-interactions on survival were evaluated by Cox proportional hazard regression model. Biological processes
and network of putative and validated targets of miRNAs were analyzed by bioinformatics.
Results: In this study, 6 interested miRNAs were identified. Survival analysis showed that high levels of
miR-326/miR-130a and low levels of miR-323/miR-329/miR-155/miR-210 were significantly associated with long OS
of GBM patients, and also showed that high miR-326/miR-130a and low miR-155/miR-210 were related with
extended PFS. Moreover, miRNA-323 and miRNA-329 were found to be increased in patients with no-recurrence or
long time to progression (TTP). More notably, our analysis revealed miRNA-interactions were more specific and
accurate to discriminate and predict OS and PFS. This interaction stratified OS and PFS related with different miRNA
levels more detailed, and could obtain longer span of mean survival in comparison to that of one single miRNA.
Moreover, miR-326, miR-130a, miR-155, miR-210 and 4 miRNA-interactions were confirmed for the first time as
independent predictors for survival by Cox regression model together with clinicopathological factors: Age, Gender
and Recurrence. Plus, the availability and rationality of the miRNA-interaction as predictors for survival were further
supported by analysis of network, biological processes, KEGG pathway and correlation analysis with gene markers.
Conclusions: Our results demonstrates that miR-326, miR-130a, miR-155, miR-210 and the 4 miRNA-interactions
could serve as prognostic and predictive markers for survival of GBM patients, suggesting a potential application in
improvement of prognostic tools and treatments.
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Glioblastoma multiforme (GBM) is the most common and
aggressive primary adult brain tumor. Despite advances in
treatment modalities, the prognosis of GBM patients is very
poor [1]. Therefore, it is urgent to develop new diagnostic
and prognostic tools and treatments which may be bene-
ficial for improving the clinical management of GBM. Cur-
rently, tumor stratifications relying on molecular profiles
are increasingly prevalent and important. Furthermore, mo-
lecular and genetic profiling studies have identified several
prognostic and predictive markers for GBM [2,3].
MicroRNAs (miRNAs or miRs), which are endogenous
non-coding small RNAs, post-transcriptionally regulate
gene expression through inhibition of translation or deg-
radation of target mRNAs [4]. MiRNAs are aberrantly
expressed in a variety of tumor types and exert important
regulations on tumor biology via acting as oncogenes or
tumor suppressors [5]. Recently, several studies indicate
that expressions of miRNAs are associated with patients’
survival and are able to function as prognostic and pre-
dictive indicators [6,7]. Moreover, it has been confirmed
that miRNA expression profiles are more accurate to clas-
sify tumors than mRNA profiles [8]. However, in the selec-
tion of miRNA markers for GBM prognosis, the applying
of following aspects, such as small dataset, explanatory va-
riables, single miRNA analysis, pre-selection of miRNAs
and use of approaches, finally lead to a variety set of diffe-
rent miRNA markers.
The main purpose of this study is to identify specific
miRNA markers that are closely associated with tumor
progression and survivals for GBM patients by analyzing
significantly altered miRNAs in a large dataset. Another
goal is to investigate the availability and rationality of
interactions of interested miRNAs as prognostic and pre-
dictive indictors for clinical outcome of GBM patients. In
this study, we found that miR-326, miR-130a, miR-155,
miR-210 and 4 miRNA-interactions could function as
prognostic and predictive markers for survival of GBM
patient.
Materials and methods
TCGA miRNA dataset and patient information
Expression data of miRNAs and genes and the corres-
ponding clinical data for glioblastoma patients were
downloaded from The Cancer Genome Atlas data portal
(July 2012) [9]. 480 GBM patients with full annotation of
Age, Gender, Survival time, Vital status, Time to progres-
sion/recurrence and miRNA values were identified in this
study. There were 186 females and 294 male patients with
ages 56.7 ± 15.9 and 58.1 ±13.6 years, respectively. Among
the whole set, 318 patients suffered from tumor recurrence
while 162 patients were kept away from progression/recur-
rence. Besides, miRNA expression data from 10 normal
brain tissues (NBT) were also collected. The collection ofthe original material and data of TCGA was conducted
in compliance with all applicable laws, regulations and
policies for the protection of human subjects, and ne-
cessary IRB approvals were obtained [9]. Totally, Expres-
sion levels of 534 human microRNAs were detected using
the Agilent 8 × 15K Human microRNA platform. The data
was quantile-normalized, collapsed within miRNAs, and
log2 transformed.
Analysis of expression levels of miRNA data in GBM
samples
To reflect the real expression profiles of miRNAs in
GBM and normal brain tissues, and to yield the detec-
tion error, we analyzed three separate batches, batch 5,
batch 16 and batch 20, from TCGA dataset with the
biggest numbers of patients, incorporating 63, 47 and
46 patient samples respectively. The level 3 data were
directly used to evaluate the relative expression levels
of miRNAs in each sample by the Z-score method [10].
The mean Z-score of each miRNA from GBM and
NBT samples was calculated and sorted in each batch
according to Z-score values in GBM samples, and the
top 20 most down-regulated and up-regulated miRNAs
were illustrated in the heatmaps pattern. Only those
microRNAs overlapping for two or three times among
three batches were selected.
Statistical computing methods
MiRNA expression profiles related to glioblastoma sur-
vival were identified using the Kaplan-Meier survival
analysis and statistical significances of overall survival
(OS) and Progression-Free survival (PFS) were deter-
mined using the Log-Rank test. Survival analysis was
performed on SPSS (version 17.0; SPSS Inc.) and the
survival curve was generated by GraphPad Prism (ver-
sion 5.04; GraphPad Software, Inc.). For survival ana-
lysis, patients with survival time lesser than 30 days were
excluded, since these patients might have died for rea-
sons other than the disease itself. A total of 458 patients
fitting this criterion were included for survival analysis.
For stratification analysis of survival, expression levels of
down-regulated miRNAs were sorted by ascending
order, while the up-regulated miRNAs were sorted by
descending order. Then, quartiles of 25%, 50% and 75%
of the sorted miRNA values were set as cutoffs for low/
high expressions of each miRNA. The survival time was
expressed as mean ± SE. To determine whether expression
levels of miRNAs were associated with Time to Progression
(TTP), discrepancies of miRNA levels between groups were
tested by student’s t-test, in terms of TTP of 9, 12 and
15 months. Likewise, according to whether there was
recurrence or not, differences of miRNA levels between
recurrent and non-recurrent groups were also tested using
student’s t-test.
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used to determine the influences of miRNA expressions as
well as clinicopathological factors (age, gender and recur-
rence) on patient survival. To adjust this potential effect
that may be confounded by age, gender and recurrence, a
multivariate Cox proportional hazard regression analysis
using all these clinicopathological factors was performed.
For analysis of interactions of two miRNAs, different quar-
tile stratifications of the expression levels of miRNAs were
set as cut-offs for high and/or low levels. The meaning of
interaction in this text was defined as combined effect or
coaction of high and/or low levels of two different miRNAs
from one patient, e.g. high/low level of miR-A and high/
low level of miR-B.
Functional Gene Ontology (GO) biological processes
terms of the putative targets of candidate miRNAs were
performed and the GO enrichment scores of target genes
were presented in the form of heatmaps [11,12]. Putative
targets of miRNAs were predicted by TargetScan Human
6.2 software [13]. Then the Functional Gene Ontology
(GO) biological processes terms of the putative targets of
candidate miRNAs, as well as the statistical analysis, were
performed by DAVID Bioinformatics Resources 6.7 [14].
The network of validated targets of interested miRNAs
was created by BisoGenet software, showing the interac-
tions of validated targets [15]. The validated targets of
interested miRNAs were obtained from Diana TarBase
v6.0 [16] and miRecords [17] and extensive Pubmed pub-
lications search. The differences were considered statisti-
cally significant at p < 0.05.
Results
Screening of the most altered miRNAs expressed in GBM
samples
To decrease the detection error within and cross
microarrays, mean Z-score values of each miRNA in
bath5, 16 and 20, which incorporate the biggest num-
bers of GBM samples in TCGA dataset, were calcu-
lated and sorted, and then the top 20 most altered
miRNAs in GBM samples were illustrated in the form
of heatmaps. After overlap analysis, expression levels of
19 miRNAs were found to be decreased in GBM sam-
ples, including miR-124a, miR-128a, miR-128b, miR-129,
miR-132, miR-137, miR-139, miR-203, miR-218, miR-323,
miR-326, miR-329, miR-330, miR-383, miR-433, miR-
485-5p, miR-491, miR-628, and miR-769-5p, while 19
miRNAs increased in GBM samples, involving let-7i,
miR-106a, miR-106b, miR-130a, miR-130b, miR-155,
miR-15a, miR-15b, miR-16, miR-195, miR-21, miR-210,
miR-23a, miR-25, miR-27a, miR-605, miR-92, miR-92b,
and miR-93 (Figure 1). Expression levels of all these
candidate miRNAs were validated by other independent
miRNAs detection studies with RNA sequencing, real-
time PCR or microarray [18-22].Correlations between miRNA expression and survival of
GBM patients
Next, using Kaplan-Meier survival analysis, correlations
between miRNA expression profiles and patient survival
were performed. Expression levels of the 38 aberrantly
expressed miRNAs were stratified by quartiles 25%, 50%
and 75%. Totally, 16 miRNAs were shown to correlate
with OS of GBM patients at different quartile stratifica-
tions (Additional file 1: Table S1). Only miR-323, miR-326,
miR-329, miR-130a, miR-155 and miR-210 were selected as
interested candidates for further analysis; this was because,
according to our knowledge, no publications on patients
survival associated with these miRNAs were reported. Our
analysis showed that low expression levels of miR-323,
miR-329, miR-155 and miR-210 significantly correlated
with long OS survival (p = 0.0043, 0.0182, 0.0191 and
0.0077, respectively), while high expression levels of
miR-326 and miR-130a were associated with long OS
survival (p = 0.0377 and 0.0099; Figure 2A). We also
showed that high levels of miR-326 and miR-130a were
associated with extended survival without tumor progres-
sion (p = 0.036 and 0.0098; Figure 2B), while low expres-
sion levels of miR-155 and miR-210 were related with
long PFS survival (p = 0.0055 and 0.0212; Figure 2B).
These results suggested that miR-326 and miR-130a may
serve as tumor suppressors, while miR-323, miR-329,
miR-155 and miR-210 serve as oncogenes.
The association among miRNAs expression and
recurrence and time to progression in GBM patients
Both tumor recurrence and time to progression (TTP) are
closely related to clinical outcome. Therefore, miRNA
expression levels were evaluated to identify the differently
expressed miRNAs according to tumor recurrence as well
as long/short time to progression. Initially, we found
that, among the 38 aberrant miRNAs, levels of miR-323
and miR-329 from the non-recurrent group (n = 162)
were significantly increased in comparison to the recur-
rent group (n = 318; p = 0.0314 and 0.0364, respectively),
whereas miR-132, miR-433, miR-628 and miR-769-5p
were marginally increased in the non-recurrent group
with miR-92b marginally decreased (Table 1). Then we
analyzed expression discrepancies of miRNAs between
long and short TTP groups. The results showed that sig-
nificant up-regulations of miR-128b and miR-323 were
observed in the group of TTP longer than 15 months
(p = 0.0420 and 0.0451), with marginal increase of miR-329
level (p = 0.0981; Table 2). Likewise, among groups of
TTP more than 9, 12 or 15months, obvious elevations
of miR-106a, miR-106b and miR-92 were exhibited
(p < 0.05), while levels of miR-21 was significantly
reduced in the group of TTP more than 9 and 12months
(p < 0.01; Table 2). However, no significant associa-
tions were observed between expression levels of miR-
Figure 1 Screening of miRNAs differentially expressed in GBM samples. Shown are top 20 most down-regulated and up-regulated miRNAs
in GBM samples within batch 5, 16 and 20 from TCGA dataset. MiRNAs overlapped no less than two times cross 3 batches are selected as
candidates for further studies. Red denotes low levels of miRNAs in GBM samples, while green denotes low levels of miRNAs in normal brain
tissues.
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time.
The association between interactions of miRNAs and
survival of GBM patients
As shown above, Low levels of miR-323 and miR-329
were associated with long survival, whereas high levels
of both miRNA were present in patients without recur-
rence or long TTP time. This inconsistence highlighted
the complication and importance of these two miRNAsin GBM tumor progression. Moreover, interactions of
miRNAs may be more specific and feasible to discrimi-
nate and predict the potential survival time of GBM
patients. Therefore, interactions of miR-323/miR-326/
miR-329 and miR-130a/miR-155/miR-210 on survival
were initially performed using Kaplan-Meier analysis
with the aim at obtaining more specific predictors.
The OS curves showed that interactions of two miRNAs
were more potent to discriminate survival time of the
same patients (Figure 3A). For instance, the OS of patients
Figure 2 Kaplan-Meier survival curves of the interested miRNAs in GBM patients. A. Analysis of the interested miRNAs on patients’ Overall
survival (OS). B. Analysis of the interested miRNAs on Progression-free survival (PFS). Survival time displayed here is mean ± SE.
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that of patients with high miR-323 and low miR-130a, with
the survival gap of 16.5 months (p = 0.0007; Figure 3 A1).
Also, the interaction of high miR-326 and high miR-130a
was associated with long OS while that of low miR-326
and low miR-130a was not, with the survival span of
21.5 months (p = 0.0003; Figure 3 A4). Furthermore,
PFS analysis showed that several interactions of two
miRNAs were more effective to distinguish survival times
of patients (Figure 3B). For example, the interaction ofTable 1 Differential expression levels of microRNAs
associated with progression/recurrence or not in GBM
patients
microRNAs Progression or Recurrence p-value
Yes No
hsa-miR-132 7.82 ± 0.51 7.92 ± 0.49 0.0605
hsa-miR-323 6.19 ± 0.29 6.26 ± 0.41 0.0314
hsa-miR-329 6.06 ± 0.20 6.11 ± 0.32 0.0364
hsa-miR-433 5.95 ± 0.16 5.98 ± 0.27 0.0739
hsa-miR-628 6.31 ± 0.19 6.34 ± 0.21 0.0843
hsa-miR-769-5p 6.48 ± 0.23 6.53 ± 0.36 0.0553
hsa-miR-92b 8.91 ± 0.67 8.28 ± 0.69 0.0682high miR-326 and high miR-130a was associated with
much longer PFS survival than that of low miR-326 and
low miR-130a, with the survival gap of 15.8 months
(Figure 3 B2). Collectively, these data indicated that
interactions of different levels of miRNAs significantly
correlated with OS and/or PFS, and it was potent and
effective to discriminate and predict the survival time
for GBM patients by this method.
Functional analyses of the interested miRNAs in GBM
The availability of interaction of miRNAs for prognosis
survival was confirmed as above. Subsequently, the ratio-
nality was further analyzed. First, GO biological processes
of putative targets of miR-323 and miR-130a were enriched
in apoptosis, cell proliferation, cell cycle, and cell adhesion/
migration, indicating their complicated biological functions
during tumor progression, while the enrichment of bio-
logical processes in cell adhesion of targets of miR-329
suggested that it mainly took part in tumor migration.
Biological processes of target genes of miR-326 and
miR-155 were dominantly associated with apoptosis
(Figure 4A). Likewise, analysis of KEGG pathway showed
that target genes of miR-323, miR-326, miR-130a and
miR-155 were all enriched in Pathways in cancer, while
miR-329 was mainly related with Adherens junction
Table 2 Differential expression levels of microRNAs associated with time to progression in patients with GBM
microRNAs Time To Progression(TTP)
< 9 months > 9 months p-value < 12 months > 12 months p-value < 15 months > 15 months p-value
hsa-miR-128b 7.56 ± 0.76 7.59 ± 0.74 0.6587 7.54 ± 0.75 7.67 ± 0.76 0.2028 7.53 ± 0.73 7.76 ± 0.81 0.0420
hsa-miR-323 6.19 ± 0.29 6.20 ± 0.28 0.5988 6.18 ± 0.29 6.22 ± 0.28 0.3012 6.18 ± 0.29 6.26 ± 0.30 0.0451
hsa-miR-329 6.06 ± 0.19 6.07 ± 0.21 0.6787 6.05 ± 0.20 6.07 ± 0.21 0.4293 6.05 ± 0.19 6.10 ± 0.22 0.0981
hsa-miR-106a 9.77 ± 0.77 9.95 ± 0.67 0.0439 9.77 ± 0.75 10.03 ± 0.67 0.0091 9.79 ± 0.73 10.03 ± 0.75 0.0305
hsa-miR-106b 10.69 ± 0.67 10.93 ± 0.58 0.0021 10.73 ± 0.67 10.91 ± 0.56 0.0398 10.75 ± 0.65 10.88 ± 0.60 0.1980
hsa-miR-21 14.22 ± 1.11 14.01 ± 1.04 0.1136 14.23 ± 1.07 13.86 ± 1.09 0.0089 14.23 ± 1.07 13.74 ± 1.08 0.0029
hsa-miR-92 10.15 ± 0.62 10.28 ± 0.64 0.0795 10.16 ± 0.62 10.32 ± 0.65 0.0497 10.16 ± 0.60 10.38 ± 0.71 0.0214
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ment of biological process and KEGG pathway of target
genes of miR-210 due to less predictive targets according to
TargetScan (Figure 4A and Additional file 2: Table S2).
Second, according to Diana TarBase and miRecords, a total
of 45 validated target genes of the four miRNAs were
observed, whereas the network was built with only 18 real
target genes of miR-130a, miR-155 and miR-210, which
exhibited direct protein-protein interactions (Figure 4B).
This simple net was composed of molecules associated
with apoptosis, cell proliferation, inflammation or carcino-
genesis, which illustrated that targets of the interested
miRNAs were not independent and they interacted with
each other. All in all, the complication and cross-talk of
the six miRNAs suggested the rationality of interactions of
miRNAs to predict the clinical outcome.
Genomic analysis of human GBM showed that EGFR,
PTEN and IDH1 were among the most altered genes
[23], which are used as commonly monitored markers
[24]. Then we tried to determine whether the 6 miRNAs
were associated with these confirmed GBM markers,
and the analysis showed that miR-326 and miR-329 were
negatively correlated with EGFR expression levels, while
miR-155 was positively related with PTEN expression
levels (Figure 4C). Meanwhile, miR-329 was also inversely
associated with IDH1 expression (Figure 4C). These cor-
relation analysis results suggested the potential application
of the interested miRNAs in predicting outcome of GBM
patients.
Interactions of miRNAs as prognostic and predictive
indicators for survival of patients with GBM
Finally, a univariate Cox proportional hazard regression
model was carried out to determine the influence of the
6 miRNAs as well as clinicopathological factors (gender,
age and recurrence) on patient survival. This univariate
analysis indicated that age, recurrence, expression levels
of miR-323, miR-326, miR-329, miR-130a, miR-155 and
miR-210 were significantly associated with survival
(Table 3). Furthermore, the interactions of miR-323 and
miR-130a, miR-326 and miR-155, miR-326 and miR-210,and miR-329 and miR-130 were more sensitively related
with survival (Table 3). Then the multivariate Cox regres-
sion model was performed to adjust the potentially con-
founded effects by age, gender and recurrence. The result
showed that miR-326, miR-130a, miR-155, miR-210 and
the four miRNA-interactions were found to be still signi-
ficantly associated with survivals, whereas miR-323 and
miR-329 had marginal impacts on survival (Table 3).
These results indicated that miR-326, miR-130a, miR-155,
miR-210 and the 4 miRNA-interactions could serve as
prognostic and predictive indicators for GBM patients,
which were independent of clinical variables.
Discussion
In this study, we identified 38 differentially expressed
miRNAs from the most significantly altered miRNAs
using data from TCGA dataset. Kaplan-Meier survival
and Cox multivariate proportional hazard model con-
firmed that the expression of miR-326, miR-130a, miR-155
and miR-210 were correlated with OS and PFS of GBM
patients and were verified for the first time as independent
predictors for GBM patient survival. More importantly,
interactions between miR-323/miR-326/miR-329 and
miR-130a/miR-155/miR-210 were also significantly related
with clinical outcome and were more sensitive to discri-
minate and predict survival time of patients. Moreover,
interactions of miR-323 and miR-130a, miR-326 and
miR-155, miR-326 and miR-210 and of miR-329 and
miR-130 were also confirmed as independent prognos-
tic indicators to clinical outcome of GBM patients. In
addition, the availability and rationality of these interac-
tions as independent prognostic and predictive indicators
were supported by integrated analysis of network, bio-
logical processes and correlation analysis with confirmed
GBM gene markers. Our results suggest a potential appli-
cation of miRNA profiles and their interactions in develop-
ment and improvement of prognostic tools and treatments.
Presently, except that presurgical prognosis relies largely
on age and Karnofsky Performance Status (KPS), no con-
vincing prognostic and predictive factors have been preva-
lent in clinical management of GBM patients, although
Figure 3 Kaplan-Meier survival analysis of the miRNA-interactions. A. Analysis of the miRNA-interaction on patients’ OS. B. Analysis of the
miRNA-interaction on patients’ PFS.
Qiu et al. Journal of Translational Medicine 2013, 11:10 Page 7 of 11
http://www.translational-medicine.com/content/11/1/10several prognostic and predictive markers or models
have been proposed or developed, such as MGMT pro-
moter methylation [25], BRAF fusions and IDH1 muta-
tions [26], subclassification based on gene expression [2],
Immunohistochemical analysis [27] and Volume-Age-KPS
(VAK) prognostic model related with MR-imaging [28].
Notably, due to development of molecular and gene pro-
files, molecular stratification for patients’ outcome are
increasingly emphasized, which leads to the extensive in-
vestigation and exploration of molecular markers.MicroRNAs, as a family of small non-coding RNAs
which are negatively involved in gene regulations, have
been recognized as important intervention targets and pre-
dictive tools for several diseases because of the stability and
convenience of miRNA detection [29-31]. Actually, several
study groups have identified a pool of miRNA signatures
for clinical outcome prediction. Through screening expres-
sion profiles of 200 miRNAs from 84 astrocytoma samples,
miR-106a, miR-181b and miR-21 were identified as diag-
nostic and prognostic markers in defining the signature of
Figure 4 Functional analysis of the interested miRNAs in GBM. A. Functional GO biological processes of putative target genes of the
6 miRNAs enriched in cell proliferation and growth, cell cycle, apoptosis and cell adhesion and migration are illustrated. Red denotes highly
significant correlation with miRNAs; black denotes lowly significant correlation with miRNAs; grey denotes no correlation. All the GO terms were
selected at the criteria of p value < 0.01. B. Network of validated target genes of miRNAs. Only the direct interactions between these target genes
are exhibited. pp: protein-protein interaction; violet: miR-155 targets; wine red: miR-210 targets; cyan: miR-130a targets. Targets of miR-323,
miR-326 and miR-329 are not involved, because of non-interaction among their few validated target genes. C. Correlation analysis of the
interested miRNAs with confirmed GBM gene markers.
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In another study including 38 GBM samples, miR-21,
miR-181c, miR-195, and miR-196b were associated with
survival of GBM patients [32]. Using TCGA dataset with
253 individuals, 23 and 19 miRNAs were defined to be
associated with OS and PFS, respectively [7]. Also, in
another publication with 222 GBM samples, a risk score,
formulated on the basis of expression signatures of 10
miRNAs, was associated with GBM patient survival,
which was suggested to predict GBM patient survival
[33]. On one hand, all these studies indicated that
miRNAs were thoroughly involved in GBM biology
and several miRNAs could act as predictive and clas-
sified indicators for GBM clinical outcome. On the
other hand, one concern has been aroused that all the
identified miRNAs were almost totally different among
these publications, which may be due to different uses
of approaches or pre-selections of target miRNAs andso on. In this study, through calculating, sorting and
overlapping mean Z-score values in GBM samples from
three separate batches, we obtained the most altered
miRNAs, which ensured that these candidate miRNAs
were more specific and accurate to distinguish expres-
sion differences between GBM and normal brain tis-
sues. Herein, the candidate miRNAs in this article were
more convincing and feasible for further potential ap-
plication in clinical practice.
This study did not follow the conventional training
and validation test analysis. However, selection bias was
yielded and validation of our findings was supported
though corroborations as follows. First of all, all miRNAs
were selected from the top most altered and overlapped
miRNAs which were sorted according to mean Z-scores
originated from 3 independent batches. Then, all expres-
sion levels of interested miRNAs have been validated on
miRNAMap and other independent miRNA detections,
Table 3 Cox regression analysis of GBM patients in relation to clinicopathological factors and miRNA expression
Variables Subset P-Value Hazard ratio 95% C.I.
Lower Upper
Univariate analysis
Age(year) 20-34/35-64/65+ 1.79E-13 2.052 1.695 2.485
Gender Male/Female 0.801753 0.973 0.787 1.204
Recurrence Yes/No 8.33E-08 0.530 0.420 0.668
MicroRNAs Percentile
Decreased (low/high) miR-323 75% 0.00430 1.411 1.114 1.786
miR-326 75% 0.03847 0.770 0.602 0.986
miR-329 75% 0.01816 1.331 1.050 1.688
Increased (high/low) miR-130a 25% 0.01028 1.381 1.079 1.766
miR-155 50% 0.01909 0.778 0.631 0.960
75% 0.01693 0.744 0.584 0.948
miR-210 25% 0.00676 0.723 0.571 0.914
50% 0.00767 0.753 0.611 0.928
Interactions M323*M130a@ 75%*25% 7E-05 1.243 1.1165 1.383
M326*M155 75%*50% 0.00432 0.861 0.778 0.954
M326*M210 75%*25% 0.00146 0.829 0.739 0.931
M329*M130 75%*25% 0.00099 1.196 1.075 1.331
Multivariate analysis
Age (year) 20-34/35-64/65+ 1.27E-08 1.797 1.469 2.200
Recurrence Yes/No 9.26E-05 0.620 0.488 0.788
miR-323 75% 0.05391 1.267 0.996 1.611
miR-326 75% 0.00567 0.701 0.544 0.901
miR-329 75% 0.07446 1.244 0.979 1.581
miR-130a 25% 0.00994 1.387 1.082 1.779
miR-155 50% 0.03335 0.796 0.646 0.982
miR-210 25% 0.01697 0.749 0.591 0.949
M323*M130a 75%*25% 0.00142 1.195 1.071 1.333
M326*M155 75%*50% 0.00097 0.840 0.758 0.932
M326*M210 75%*25% 0.00026 0.806 0.718 0.905
M329*M130 75%*25% 0.00342 1.177 1.055 1.313
@M denotes miR.
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thermore, biological function of the interested miRNAs
and their target genes were analyzed, which may directly
reflect the roles of miRNAs in tumor progression.
Among the 6 interested miRNAs, miR-326 was reported
to inhibit GBM cell growth, whereas miR-155 was shown
to promote GBM proliferation [34,35], which could be
explained by that the target genes of miR-326 and miR-155
were mostly related with apoptosis (Figure 4A). However,
according to our knowledge, there is no study reporting the
associations between OS and PFS and miR-326/miR-155,
while our result for the first time showed that high level of
miR-326 and low level of miR-155 were significantly asso-
ciated with long OS and PFS. Likewise, we first found thatlow levels of miR-323 and miR-329 correlated with long
OS, and high level of miR-130a and low level of miR-210
were linked with extended either OS or PFS. These survival
analyses indicated that miR-326 and miR-130a functioned
as tumor suppressors while the others as oncogenes. How-
ever, it should be noted that expression levels of miR-323/
miR-329 were elevated in no-recurrent and longer TTP
patients, which were not consistent with oncogenic roles of
miR-323/miR-329. Several reasons may be responsible for
this inconsistence. Initially, it has been confirmed that on
average one miRNA has approximately 100 target sites,
regulating a large fraction of protein-coding genes involving
in several biological processes, such as cell proliferation,
apoptosis, and cell motion etc. [36]. Second, putative targets
Qiu et al. Journal of Translational Medicine 2013, 11:10 Page 10 of 11
http://www.translational-medicine.com/content/11/1/10of miR-323 and miR-329 incorporated a family of mole-
cules associated with cell migration and adhesion as
shown in Figure 4A. Furthermore, the recurrence of
GBM is related with these migration and adhesion genes
[37]. Herein, miR-323/miR-329 may be involved in migra-
tion inhibition in non-recurrent patients through elevation
of their expression levels. This inconsistence also occurred
to miR-130a, which was shown to not only inhibit tumor
suppressor RUNX3 in hepatocellular carcinoma [38] but
also suppress proto-oncogene MET in lung cancer. This
may be due to extensive distribution of predictive targets of
miR-130a [39]. To date, there is no functional study related
with miR-323, miR-329, miR-130a and miR-210 in GBM.
The complication of biological function of these miRNAs
also indicated that it may be more reasonable to study their
interactions, because of the multifactorial nature of the
disease, and the distinguishing feature of miRNAs that
an average miRNA has approximately 100 target sites
and regulates a large fraction of protein-coding genes,
which form a regulatory network [36,40]. OS and PFS
analysis showed that the two-miRNA interaction were
more sensitive and accurate to discriminate and predict the
survival time in relative to one single miRNA. For instance,
the longest gap of mean survival time of OS and PFS
occurred on miR-130a, with 8.1 months and 5.4 months,
respectively. However, the longest gap of mean survival of
OS and PFS was 20.9 months and 15.8 months related with
the interaction of miR-326 and miR-130a. Moreover, this
interaction effect made the stratification of patients’ survival
more detailed and specific. For example, the mean OS of
patients with high and low miR-130a was 26.6 months and
18.5 months respectively, whereas the corresponding sur-
vival of patients with both low miR-323 and miR-130a was
30.9months, and that with both low miR-323 and high
miR-130a was 14.4 months. Therefore, the interaction ana-
lysis of miRNAs may provide new views on diagnosis and
prognosis of GBM patients.
In summary, we identify miR-326, miR-130a, miR-155
and miR-210 markers related with survival of GBM. More
importantly, we determine the availability and rationality
of 4 miRNA-interactions as more specific and accurate
prognostic and predictive indicators to clinical outcome of
GBM patients, implying the application for diagnostic and
prognostic tools and treatments.Additional files
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